Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor.

DeMarzo AM, Onate SA, Nordeen SK, Edwards DP

Biochemistry, (43):10491-10501 1992

MED: 1420166

The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways.

Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP

Proc Natl Acad Sci U S A, (10):4441-4445 1993

MED: 8389450

Title not supplied

Horwitz

Proc Annu Meet Am Assoc Cancer Res 1994

Switching agonistic, antagonistic, and mixed transcriptional responses to 11 beta-substituted progestins by mutation of the progesterone receptor.

Garcia T, Benhamou B, Gofflo D, Vergezac A, Philibert D, Chambon P, Gronemeyer H

Mol Endocrinol, (12):2071-2078 1992

MED: 1337143

Pharmacokinetic study of orally administered RU 486 in non-pregnant women.

He CH, Shi YE, Ye ZH, Zhang GG, Jiang NX, Van Look PF, Fotherby K

Contraception, (4):449-460 1989

MED: 2582770

Pharmacodynamics of the antiprogesterone RU486 in women after oral administration.

Liu JH, Garzo VG, Yen SS

Fertil Steril, (2):245-249 1988

MED: 2840310

Pharmacokinetics and metabolism of RU 486.

Lahteenmaki P, Heikinheimo O, Croxatto H, Spitz I, Shoupe D, Birgerson L, Luukkainen T

J Steroid Biochem, (4-6):859-863 1987

MED: 3695508

Title not supplied

Grimaldi

CR Acad Sci Paris 1992

Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography.

Heikinheimo O, Tevilin M, Shoupe D, Croxatto H, Lahteenmaki P

Contraception, (6):613-624 1986

MED: 3829676

Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models.

Schneider MR, Michna H, Nishino Y, el Etreby MF

J Steroid Biochem Mol Biol, (6):783-787 1990

MED: 2285591